Person:
ÇOBAN, EZGİ

Profile Picture
Status
Kurumdan Ayrılmıştır
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
EZGİ
Last Name
ÇOBAN
Name
Email Address
Birth Date

Filters

2017 - 20182
Reset filters

Settings

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    A Primary Adenosquamous Carcinoma of the Stomach: Report of Two Cases
    (2017-07-01) Gecer, MELİN; Unver, NURCAN; HASBAHCECI, Mustafa; Gucin, ZÜHAL; Tosuner, ZEYNEP; Akcakaya, ADEM; Arici, Sema; GEÇER, MELİN; ÜNVER, NURCAN; GÜCİN, ZÜHAL; TOSUNER, ZEYNEP; ÇOBAN, EZGİ; AKÇAKAYA, ADEM; ARICI, DILEK SEMA
    Primary gastric adenosquamous carcinomas are extremely rare tumors. A gradual transition between the malignant glandular and squamous components of the tumor is seen on performing a histopathological evaluation. These tumors are known to have poorer clinical outcomes than conventional adenocarcinomas. We aimed to present two cases of primary adenosquamous carcinomas that were diagnosed at the later stage in our institute.
  • No Thumbnail Available
    PublicationMetadata only
    Role of Urotensin-2 in 5-Fluorouracil-Related Arterial Vasoconstriction in Cancer Patients
    (2018-01-01) Seker, MESUT; ISEN, Hayati C.; Cevirme, NİDAL; Aydin, Sinem; Bilici, Ahmet; COBAN, EZGİ; Bulut, HURİ; YASIN, Ayse I.; Demir, TARIK; Aliyev, ALTAY; Kocyigit, ABDÜRRAHİM; Turk, Haci M.; ŞEKER, MESUT; ÇEVİRME, NİDAL; BULUT, HURI; ÇOBAN, EZGİ; DEMİR, TARıK; ALİYEV, ALTAY; KOÇYİĞİT, ABDÜRRAHİM; TÜRK, HACI MEHMET
    Background: The aim of this study was to identify the possible relationship of 5-fluorouracil (5-FU)-related arterial vasoconstriction with urotensin-2 (UT-2), which has a high potential as an endogenic vasoconstrictor. Methods: We assigned the patients to 1 of 3 groups. Patients in group 1 received a bolus of 5-FU, those in group 2 a continuous infusion (CI) of 5-FU, and those in group 3 no 5-FU, which was also a control group. Pre- and post-treatment UT-2 levels and brachial arterial diameters were measured and recorded in all patients. Results: 132 patients were included in the study. Pre-and post-treatment brachial artery diameters were similar in all groups: in group 1 (3.28 +/- 0.52 vs. 3.25 +/- 0.44 mm, p = 0.740), in group 2 (3.57 +/- 0.47 vs. 3.46 +/- 0.45 mm, p = 0.441) and in the control group (3.51 +/- 0.52 vs. 3.25 +/- 0.44 mm, p = 0.818). Pre-and post-treatment UT-2 levels were significantly different in each group: in group 1 (39.5 +/- 30.9 vs. 56.7 +/- 27.1 ng/ml, p = 0.0001), in group 2 (37.7 +/- 33.7 vs. 62.5 +/- 37.7 ng/ml, p = 0.0001) and in the control group (52.9 +/- 40.2 vs. 60.8 +/- 40.7 ng/ml, p = 0.006). Conclusion: Our findings suggest that UT-2 has a high potential as a vasoconstrictor agent in our bodies and its level increases through a bolus or CI 5-FU. Increased UT-2 levels are likely to play a role in 5-FU-related cardiac toxicity pathogenesis. (c) 2018 S. Karger GmbH, Freiburg